1. Home
  2. MERC vs ACRV Comparison

MERC vs ACRV Comparison

Compare MERC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercer International Inc.

MERC

Mercer International Inc.

HOLD

Current Price

$0.59

Market Cap

60.2M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.73

Market Cap

68.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MERC
ACRV
Founded
1968
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Paper
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.2M
68.5M
IPO Year
2005
2022

Fundamental Metrics

Financial Performance
Metric
MERC
ACRV
Price
$0.59
$1.73
Analyst Decision
Hold
Buy
Analyst Count
3
4
Target Price
$2.25
$11.67
AVG Volume (30 Days)
492.3K
400.2K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
7.01%
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
$1,169,145,000.00
N/A
Revenue This Year
$13.75
N/A
Revenue Next Year
$10.12
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
25.50
N/A
52 Week Low
$0.53
$1.20
52 Week High
$3.38
$3.56

Technical Indicators

Market Signals
Indicator
MERC
ACRV
Relative Strength Index (RSI) 48.62 51.98
Support Level $0.54 $1.58
Resistance Level $0.72 $2.20
Average True Range (ATR) 0.06 0.09
MACD 0.01 -0.00
Stochastic Oscillator 60.48 74.07

Price Performance

Historical Comparison
MERC
ACRV

About MERC Mercer International Inc.

Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: